Jobs / United States / Astrazeneca Pharmaceuticals Lp
Director, Clinical AI Research & Evaluation
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Cambridge Kendall SQ - MA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Job Title: Director, Clinical AI Research & Evaluation Introduction to role: About AISI AI Science & Innovation (AISI) sits at the centre of AstraZeneca’s R&D AI transformation within Enterprise AI Unit (EAI). Our remit is to build, buy, and deliver the AI models and agents that change pipeline outcomes across discovery, translational science, biomarkers, and clinical development, ultimately improve patients’ lives. The opportunity We are building an end-to-end Enterprise AI engine that unites data foundations, AI models, platforms, and business-facing applications to accelerate results across the value chain. Success comes from reusing what already works, sharing ideas across teams, and scaling impact rather than building in isolation. Role overview AstraZeneca is building an AI capability for Clinical Development that will change how trials are designed, conducted, monitored, and analyzed. We are hiring a Director, Clinical AI Research & Evaluation to lead the scientific foundation that makes clinical AI systems trustworthy, measurable, and ready to scale into regulated practice. The role sits in the Clinical AI Applied Science & Translation team, based in Boston, MA. You will set the research agenda for how clinical AI systems are evaluated, how human professionals interact with AI in clinical workflows, and what evidence standards must exist before a system can be trusted at scale. This is a research leadership role with delivery accountability. You will define the methodology as we practice it, while remaining close enough to the work to credibly challenge it. You will direct a team of scientists and engineers, partner with product owners and Engineering, and establish evaluation and human-factors practices that extend across the Clinical Operations and Development AI portfolio. The initial focus for this role is an agentic system being built to reduce the administrative burden for research associates conducting trials at sites but with the expectation that patterns discovered and built here will scale to additional clinical AI system we develop along the way. The strongest candidates combine deep research expertise in AI evaluation or human computer interaction with the practical grounding to close the distance between principled methodology and working with and building regulated software. Accountabilities: Research Leadership • Define and own the scientific methodology for evaluating clinical AI systems: evaluation harnesses, benchmark construction, failure mode taxonomy, red-team protocols, and monitoring strategies across the system lifecycle. Build a structured catalog of ways the system can fail clinically and run structured testing before any deployment. • Advance methods for evaluation in clinically complex conditions such as noisy or delayed ground truth, expert disagreement, multi-step agentic workflows, human in-the-loop performance, and automation bias or where simple metrics fail. • Develop human factors and workflow-integration methods beyond usability testing: how AI output shapes human judgment, what oversight mechanisms are effective, how clinical professionals calibrate trust in AI-assisted work, and what human review effectively ensure patient safety. • Publish and communicate findings externally where appropriate to build AstraZeneca’s scientific credibility and attract research talent. Applied Delivery • Design and implement evaluation frameworks that determine when a system is ready to move from prototype to controlled pilot, from pilot to deployment, and from non-GxP to regulated use. • Participating in defining human review requirements for user facing AI outputs: what requires sign-off before action, what can be surfaced directly, and how oversight should be structured in the validation pl